Floatz logo

Epo

Ischemic Stroke

Yonsei UniversityPhase 1/2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
65/ 100

Competitive context

83 Active assets in the Ischemic Stroke cohort.

Asset / SponsorPhaseRating
Ticagrelor
Sichuan Provincial People's Hospital
Phase 4BBB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Stanford University
Phase 4BBB
Argatroban
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
Acetylsalicylic Acid
Nanfang Hospital, Southern Medical University
Phase 4BB
Plavix
Nanfang Hospital, Southern Medical University
Phase 4BB

View all 50 →

Same molecule, other indications

Epo is also rated in:

peritoneal neoplasmDormant
B
Indicative ·
57 / 100
View asset →
fallopian tube cancerDormant
CCC
Indicative ·
51 / 100
View asset →
Neurological DiseasesDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →